These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35731428)

  • 21. Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis.
    Rosenblatt R; Mehta A; Snell D; Hissong E; Kierans AS; Kumar S
    Dig Dis Sci; 2019 Jan; 64(1):262-268. PubMed ID: 30269271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis.
    Tanaka M; Riddell RH; Saito H; Soma Y; Hidaka H; Kudo H
    Scand J Gastroenterol; 1999 Jan; 34(1):55-67. PubMed ID: 10048734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis.
    Hoffmann P; Jung V; Behnisch R; Gauss A
    World J Gastroenterol; 2020 Dec; 26(46):7367-7381. PubMed ID: 33362390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonalcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm.
    Cho Y; Lim SK; Joo SK; Jeong DH; Kim JH; Bae JM; Park JH; Chang MS; Lee DH; Jung YJ; Kim BG; Kim D; Lee KL; Kim W
    Liver Int; 2019 Sep; 39(9):1722-1731. PubMed ID: 31162812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of Hepatobiliary Manifestations and Concomitant Liver Disease in Inflammatory Bowel Disease Patients.
    Silva J; Brito BS; Silva INN; Nóbrega VG; da Silva MCSM; Gomes HDN; Fortes FM; Pimentel AM; Mota J; Almeida N; Surlo VC; Lyra A; Rocha R; Santana GO
    Biomed Res Int; 2019; 2019():7604939. PubMed ID: 30834274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease.
    Petta S; Tuttolomondo A; Gagliardo C; Zafonte R; Brancatelli G; Cabibi D; Cammà C; Di Marco V; Galvano L; La Tona G; Licata A; Magliozzo F; Maida C; Marchesini G; Merlino G; Midiri M; Parrinello G; Torres D; Pinto A; Craxì A
    Medicine (Baltimore); 2016 Apr; 95(16):e3446. PubMed ID: 27100443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review.
    Martínez-Domínguez SJ; García-Mateo S; Laredo V; Gargallo-Puyuelo CJ; Gallego Llera B; López de la Cruz J; Gomollón F
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk Factors for the Occurrence and Severity of Vertebral Fractures in Inflammatory Bowel Disease Patients: A Nationwide Population-Based Cohort Study.
    Choi A; Jung SH; Kim S; Lee JS
    J Korean Med Sci; 2023 Jul; 38(28):e210. PubMed ID: 37463684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
    Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
    J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High incidence of non-alcoholic fatty liver disease in patients with Crohn's disease but not ulcerative colitis.
    Li D; Lu C; Yu C
    Int J Clin Exp Pathol; 2017; 10(10):10633-10639. PubMed ID: 31966406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
    ; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
    J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
    Simon TG; Roelstraete B; Sharma R; Khalili H; Hagström H; Ludvigsson JF
    Hepatology; 2021 Nov; 74(5):2410-2423. PubMed ID: 33811766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
    Simon TG; Roelstraete B; Khalili H; Hagström H; Ludvigsson JF
    Gut; 2021 Jul; 70(7):1375-1382. PubMed ID: 33037056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
    Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
    Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease.
    McHenry S; Tirath A; Tsai R; Sharma Y; Flores AG; Davidson NO; Fowler KJ; Ciorba MA; Deepak P
    Inflamm Bowel Dis; 2020 Nov; 26(12):1917-1925. PubMed ID: 31907542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.